Health
China Sinopharm’s potential COVID-19 vaccine triggers antibodies in clinical trials: Journal – The Jakarta Post – Jakarta Post
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The candidate has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.
Sinopharm is testing the potential vaccine in the United Arab Emirates in a Phase 3 tria…
-
Noosa News20 hours agoHelicopter pilots saving lives, providing food and fodder in flooded outback Queensland
-
Noosa News23 hours ago’Lethal new opioids’ prompt Wide Bay pill testing call
-
General19 hours agoInternal Revenue Service starts cutting 20,000 workers
-
Noosa News19 hours agoMan killed, woman seriously injured in collision in Wongabel, Atherton Tablelands, Queensland